CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Microbot Medical Inc. - MBOT CFD

    1.23
    1.61%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 1.24
    Open* 1.23
    1-Year Change* -72.85%
    Day's Range* 1.22 - 1.24
    52 wk Range 1.00-4.65
    Average Volume (10 days) 50.14K
    Average Volume (3 months) 1.92M
    Market Cap 15.80M
    P/E Ratio -100.00K
    Shares Outstanding 11.71M
    Revenue N/A
    EPS -1.20
    Dividend (Yield %) N/A
    Beta 3.19
    Next Earnings Date Nov 24, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 30, 2023 1.24 -0.01 -0.80% 1.25 1.28 1.21
    Nov 29, 2023 1.24 -0.06 -4.62% 1.30 1.32 1.21
    Nov 28, 2023 1.28 -0.06 -4.48% 1.34 1.34 1.28
    Nov 27, 2023 1.34 -0.03 -2.19% 1.37 1.37 1.29
    Nov 24, 2023 1.31 0.00 0.00% 1.31 1.42 1.31
    Nov 22, 2023 1.30 -0.05 -3.70% 1.35 1.35 1.28
    Nov 21, 2023 1.33 0.00 0.00% 1.33 1.39 1.30
    Nov 20, 2023 1.35 0.01 0.75% 1.34 1.44 1.34
    Nov 17, 2023 1.34 0.01 0.75% 1.33 1.36 1.33
    Nov 16, 2023 1.33 -0.04 -2.92% 1.37 1.38 1.33
    Nov 15, 2023 1.40 0.06 4.48% 1.34 1.43 1.32
    Nov 14, 2023 1.36 0.03 2.26% 1.33 1.38 1.33
    Nov 13, 2023 1.32 0.01 0.76% 1.31 1.33 1.27
    Nov 10, 2023 1.32 -0.06 -4.35% 1.38 1.38 1.30
    Nov 9, 2023 1.36 -0.08 -5.56% 1.44 1.44 1.35
    Nov 8, 2023 1.46 0.09 6.57% 1.37 1.51 1.37
    Nov 7, 2023 1.36 0.03 2.26% 1.33 1.37 1.33
    Nov 6, 2023 1.34 -0.05 -3.60% 1.39 1.41 1.28
    Nov 3, 2023 1.40 0.17 13.82% 1.23 1.41 1.23
    Nov 2, 2023 1.26 0.08 6.78% 1.18 1.27 1.18

    Microbot Medical Inc. Events

    Time (UTC) Country Event
    Friday, March 29, 2024

    Time (UTC)

    20:00

    Country

    US

    Event

    Q4 2023 Microbot Medical Inc Earnings Release
    Q4 2023 Microbot Medical Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 13.281 11.357 9.089 7.24 7.244
    Selling/General/Admin. Expenses, Total 5.769 5.406 5.884 4.362 4.832
    Research & Development 7.41 5.875 3.137 2.822 2.702
    Operating Income -13.281 -11.357 -9.089 -7.24 -7.244
    Interest Income (Expense), Net Non-Operating 0.118 0.044 -0.08 -0.103 -0.016
    Other, Net
    Net Income Before Taxes -13.168 -11.313 -9.169 -7.247 -7.26
    Net Income After Taxes -13.168 -11.313 -9.169 -7.247 -7.26
    Net Income Before Extra. Items -13.168 -11.313 -9.169 -7.247 -7.26
    Net Income -13.168 -11.313 -9.169 -7.247 -7.26
    Income Available to Common Excl. Extra. Items -13.168 -11.313 -9.169 -7.247 -7.26
    Income Available to Common Incl. Extra. Items -13.168 -11.313 -9.169 -7.247 -7.26
    Diluted Net Income -13.168 -11.313 -9.169 -7.247 -7.26
    Diluted Weighted Average Shares 7.26034 7.10813 7.11775 4.26721 2.90425
    Diluted EPS Excluding Extraordinary Items -1.81369 -1.59156 -1.28819 -1.6983 -2.49978
    Diluted Normalized EPS -1.813 -1.59156 -1.28819 -1.7208 -2.49978
    Unusual Expense (Income)
    Depreciation / Amortization 0.102 0.076 0.068 0.084 0.054
    Other Operating Expenses, Total 0 -0.028 -0.344
    Gain (Loss) on Sale of Assets -0.005 0 0.096 0
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 2.324 2.919 3.068 3.474 3.563
    Selling/General/Admin. Expenses, Total 0.959 1.302 1.184 1.521 1.37
    Research & Development 1.365 1.617 1.884 1.953 2.193
    Operating Income -2.324 -2.919 -3.068 -3.474 -3.563
    Interest Income (Expense), Net Non-Operating 0.037 0.066 0.075 0.006 0.05
    Net Income Before Taxes -2.287 -2.853 -2.998 -3.468 -3.513
    Net Income After Taxes -2.287 -2.853 -2.998 -3.468 -3.513
    Net Income Before Extra. Items -2.287 -2.853 -2.998 -3.468 -3.513
    Net Income -2.287 -2.853 -2.998 -3.468 -3.513
    Income Available to Common Excl. Extra. Items -2.287 -2.853 -2.998 -3.468 -3.513
    Income Available to Common Incl. Extra. Items -2.287 -2.853 -2.998 -3.468 -3.513
    Diluted Net Income -2.287 -2.853 -2.998 -3.468 -3.513
    Diluted Weighted Average Shares 9.19881 8.0133 7.71698 7.10813 7.10813
    Diluted EPS Excluding Extraordinary Items -0.24862 -0.35603 -0.38849 -0.48789 -0.49422
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.24862 -0.35603 -0.38785 -0.48789 -0.49422
    Gain (Loss) on Sale of Assets -0.005
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 8.814 15.879 25.253 35.936 5.831
    Cash and Short Term Investments 8.205 15.492 24.648 31.292 5.238
    Cash & Equivalents 2.442 13.493 19.65 28.771 5.238
    Total Receivables, Net 0.103 0.174 0.07 0.101 0.065
    Prepaid Expenses 0.429 0.126 0.451 0.185 0.091
    Other Current Assets, Total 0.077 0.087 0.084 4.358 0.437
    Total Assets 9.537 16.767 26.279 37.126 6.09
    Property/Plant/Equipment, Total - Net 0.723 0.888 1.026 1.19 0.259
    Property/Plant/Equipment, Total - Gross 1.11 1.177 1.239 1.335 0.391
    Accumulated Depreciation, Total -0.387 -0.289 -0.213 -0.145 -0.132
    Total Current Liabilities 2.069 1.984 1.345 4.826 4.76
    Accounts Payable 0.116 0.279 0.275 0.284 0.63
    Accrued Expenses 1.953 1.705 1.07 0.33 3.442
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 4.212 0.688
    Total Liabilities 2.248 2.386 1.971 5.586 4.768
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt
    Other Liabilities, Total 0.179 0.402 0.626 0.76 0.008
    Total Equity 7.289 14.381 24.308 31.54 1.322
    Common Stock 0.08 0.072 0.072 0.072 0.031
    Additional Paid-In Capital 75.97 69.902 68.516 69.954 32.53
    Retained Earnings (Accumulated Deficit) -68.761 -55.593 -44.28 -35.111 -27.864
    Other Equity, Total
    Total Liabilities & Shareholders’ Equity 9.537 16.767 26.279 37.126 6.09
    Total Common Shares Outstanding 7.89063 7.10813 7.10813 7.18563 3.01234
    Treasury Stock - Common 0 -3.375 -3.375
    Short Term Investments 5.763 1.999 4.998 2.521
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 8.407 10.339 5.581 8.814 6.603
    Cash and Short Term Investments 8.153 9.92 5.057 8.205 6.331
    Cash & Equivalents 1.335 5.721 2.15 2.442 4.332
    Short Term Investments 6.818 4.199 2.907 5.763 1.999
    Prepaid Expenses 0.208 0.371 0.475 0.429 0.193
    Other Current Assets, Total 0.046 0.048 0.049 0.077 0.079
    Total Assets 8.888 10.884 6.208 9.537 7.409
    Property/Plant/Equipment, Total - Net 0.481 0.545 0.627 0.723 0.806
    Total Current Liabilities 1.491 1.324 1.233 2.069 1.65
    Accounts Payable 0.238 0.24 0.224 0.116 0.287
    Accrued Expenses 1.253 1.084 1.009 1.953 1.363
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 1.53 1.416 1.36 2.248 1.876
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0.039 0.092 0.127 0.179 0.226
    Total Equity 7.358 9.468 4.848 7.289 5.533
    Common Stock 0.118 0.118 0.083 0.08 0.072
    Additional Paid-In Capital 83.587 83.251 76.379 75.97 71.224
    Retained Earnings (Accumulated Deficit) -76.347 -73.901 -71.614 -68.761 -65.763
    Total Liabilities & Shareholders’ Equity 8.888 10.884 6.208 9.537 7.409
    Total Common Shares Outstanding 11.7073 11.7073 8.13063 7.89063 7.10813
    Total Receivables, Net 0.103
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -13.168 -11.313 -9.169 -7.247 -7.24
    Cash From Operating Activities -11.549 -9.354 -7.252 -6.451 -5.31
    Cash From Operating Activities 0.102 0.076 0.068 0.084 0.054
    Non-Cash Items 1.745 1.386 1.867 0.978 1.453
    Changes in Working Capital -0.228 0.497 -0.018 -0.266 0.423
    Cash From Investing Activities -3.836 3.2 -2.768 -2.453 -0.223
    Capital Expenditures -0.084 -0.069 -0.091 -0.216 -0.223
    Cash From Financing Activities 4.324 0 -3.375 36.77 -0.018
    Financing Cash Flow Items 0 -3.375 -0.018
    Issuance (Retirement) of Stock, Net 4.324 36.77 0
    Issuance (Retirement) of Debt, Net
    Net Change in Cash -11.061 -6.154 -13.395 27.866 -5.551
    Other Investing Cash Flow Items, Total -3.752 3.269 -2.677 -2.237
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -2.853 -13.168 -10.17 -6.702 -3.189
    Cash From Operating Activities -3.203 -11.549 -9.086 -6.131 -3.007
    Cash From Operating Activities 0.025 0.102 0.069 0.044 0.021
    Non-Cash Items 0.385 1.745 1.322 0.862 0.43
    Changes in Working Capital -0.76 -0.228 -0.307 -0.335 -0.269
    Cash From Investing Activities 2.883 -3.836 -0.083 -0.078 -0.016
    Capital Expenditures 0 -0.084 -0.083 -0.078 -0.016
    Other Investing Cash Flow Items, Total 2.883 -3.752 0 0 0
    Cash From Financing Activities 4.324
    Financing Cash Flow Items
    Net Change in Cash -0.32 -11.061 -9.169 -6.209 -3.023
    Issuance (Retirement) of Stock, Net 4.324
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Chasing Value Asset Management, Inc. Investment Advisor/Hedge Fund 5.216 610657 0 2023-09-08
    Armistice Capital LLC Hedge Fund 3.2906 385246 -214754 2023-06-30 MED
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.2322 261336 513 2023-06-30 LOW
    Bornstein (Yoseph) Individual Investor 2.0673 242028 0 2023-09-08
    BlackRock Institutional Trust Company, N.A. Investment Advisor 1.1771 137808 -13620 2023-06-30 LOW
    MEDX Ventures Group LLC Venture Capital 1.1689 136847 0 2023-09-08
    AlphaCentric Advisors LLC. Investment Advisor 0.8542 100000 0 2023-06-30 HIGH
    Pacific View Asset Management, LLC Investment Advisor/Hedge Fund 0.8542 100000 0 2023-06-30 MED
    Renaissance Technologies LLC Hedge Fund 0.7491 87695 67300 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.452 52922 0 2023-06-30 LOW
    BNY Mellon Asset Management Investment Advisor 0.4385 51334 -1393 2023-09-30 LOW
    Morgan Stanley Smith Barney LLC Investment Advisor 0.342 40038 4600 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.2227 26070 0 2023-06-30 LOW
    PlainsCapital Corporation Investment Advisor 0.1629 19075 19075 2023-06-30 MED
    Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.1149 13446 0 2023-06-30 LOW
    Wells Fargo Advisors Research Firm 0.1084 12685 12550 2023-06-30 LOW
    Taylor Frigon Capital Management LLC Investment Advisor 0.1068 12500 12500 2023-09-30 LOW
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.0874 10231 -55976 2023-06-30 LOW
    Millennium Management LLC Hedge Fund 0.0873 10219 -4643 2023-06-30 HIGH
    UBS Financial Services, Inc. Investment Advisor 0.0777 9100 4559 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Microbot Medical Inc. Company profile

    About Microbot Medical Inc

    Microbot Medical Inc. is a pre-clinical medical device company. The Company is focused on the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Its technological platforms are comprised of ViRob, TipCAT and Liberty, including certain CardioSert assets. Using the ViRob platform, Microbot is developing the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH). Utilizing the Liberty and CardioSert platforms, it is developing disposable robot for various endovascular interventional procedures. ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. TipCAT is a disposable self-propelled locomotive device, designed to advance in tubular anatomies. Liberty is a disposable robotic system, designed to move guidewires and over-the-wire devices, such as microcatheters within the body’s vasculature.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Microbot Medical Inc revenues was not reported. Net loss increased 14% to $7.5M. Higher net loss reflects Research and development increase of 63% to $3.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.92 to -$1.05.

    Equity composition

    Common $.1 Par, 07/11, 250M auth., 13,784,019 issd,. Insiders control approx. 8.68%. IPO 3/92, 2.25M shares @ $11.00 by Robertson, Stephens & Co. PO 9/95, 2.3M shares @ $9.375. 10/93, *5/00, Name changed from Cytotherapeutics, Inc. PO: 11/08, 13.8M shares. 07/11, 1-for-10 reverse stock split. 05/16 1-for-12 reverse stock split.

    Industry: Biotechnology & Medical Research (NEC)

    25 Recreation Park Dr Suite 108
    HINGHAM
    MASSACHUSETTS 02043
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    Gold

    2,049.50 Price
    +0.460% 1D Chg, %
    Long position overnight fee -0.0196%
    Short position overnight fee 0.0114%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    XRP/USD

    0.61 Price
    -0.110% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    BTC/USD

    38,429.45 Price
    +1.690% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Oil - Crude

    76.22 Price
    +1.340% 1D Chg, %
    Long position overnight fee -0.0165%
    Short position overnight fee -0.0054%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading